Skip to content
Parakho

Sanofi Consumer Healthcare India Ltd

NSE SANOFICONRBSE 544250

Q1 FY27, unaudited

Revenue
₹235.70 Cr
Profit after tax
₹68.80 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year ago6M FY27
Revenue from operations235.70+6.70%464.90
Other income6.30+12.50%11.90
Total income242.00+6.84%476.80
Employee benefit expense31.30−2.19%64.40
Finance costs0.40−20.00%0.90
Depreciation & amortisation3.30+10.00%6.50
Total expenses150.10−2.66%294.20
Profit before tax91.90+16.48%182.60
Tax expense23.10+26.92%46.00
Profit after tax68.80+13.34%136.60
Total comprehensive income68.80+13.34%136.60
Earnings per share
Earnings per share, basic₹29.87₹59.31
Earnings per share, diluted₹29.87₹59.31

Q1 FY27 and 6M FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Sanofi Consumer Healthcare India Ltd has not filed a concall transcript in the last 4 quarters.

Filings

12 shown · 32 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 12 Oct 2026.